Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma

Glioblastoma (GBM) is the most common malignant brain tumor in adults. We designed an adeno-associated virus (AAV) vector for intracranial delivery of secreted, soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL) to GBM tumors in mice and combined it with the TRAIL-sensitizing cardiac glycoside, lanatoside C (lan C). We applied this combined therapy to two different GBM models using human U87 glioma cells and primary patient-derived GBM neural spheres in culture and in orthotopic GBM xenograft models in mice.

Source: Molecular Oncology - December 10, 2015 Category: Cancer & Oncology Authors: Matheus H.W. Crommentuijn, Casey A. Maguire, Johanna M. Niers, W. Peter Vandertop, Christian E. Badr, Thomas Würdinger, Bakhos A. Tannous Source Type: research